<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582539</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 00928-105</org_study_id>
    <nct_id>NCT04582539</nct_id>
  </id_info>
  <brief_title>To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.</brief_title>
  <official_title>A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and&#xD;
      tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants&#xD;
      with MDS or MM who are transfusion-dependent or present with symptomatic anemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">December 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-related adverse events</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>To determine the safety and tolerability of INCB000928 administered as monotherapy in participants with MDS or MM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with anemia response (for TI patients at baseline)</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as an Hgb increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of anemia response</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as the interval from the first onset of anemia response to the earliest date of loss of anemia response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with RBC-TI (for TD at baseline)</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as the absence of any RBC transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of RBC-TI period</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as duration of time for which participants are transfusion independent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of RBC transfusion</measure>
    <time_frame>Through weeks 12 and 24</time_frame>
    <description>Defined as the average number of RBC units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in mean Hgb</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as the increase from baseline in the mean Hgb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS Participants only : Overall Response Rate</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as the proportion of participants with CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS Participants only : Progression Free Survival</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as the interval from the first dose of study drug until the first documented progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS Participants only : Leukemia Free Survival</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as the interval from the first dose of study drug until the first documented leukemia transformation or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM participants only : Overall Response Rate</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as the proportion of participants with stringent CR, CR, very good PR, and PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM Participants only : Progression Free Survival</measure>
    <time_frame>Approximately up to 7 months</time_frame>
    <description>Defined as the interval from the first dose of study drug until the first documented progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>C1D1 and C1D15</time_frame>
    <description>Maximum plasma concentration of INCB000928</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>C1D1 and C1D15</time_frame>
    <description>Time to reach maximum (peak) plasma concentration of INCB000928</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>C1D1 and C1D15</time_frame>
    <description>Area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepcidin levels</measure>
    <time_frame>Approximately upto 7 months</time_frame>
    <description>Effect of INCB000928 on hepcidin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron Homeostasis</measure>
    <time_frame>Approximately upto 7 months</time_frame>
    <description>Effect of INCB000928 on iron homeostasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoiesis</measure>
    <time_frame>Approximately upto 7 months</time_frame>
    <description>Effect of INCB000928 on erythropoiesis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>INCB000928</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB000928</intervention_name>
    <description>INCB000928 will be administered once daily.</description>
    <arm_group_label>INCB000928</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agreement to avoid pregnancy or fathering children.&#xD;
&#xD;
          -  Participants who are transfusion-dependent or present with symptomatic anemia&#xD;
&#xD;
        For MDS participants:&#xD;
&#xD;
          -  Ineligible to receive or have not responded to available therapies for anemia such as&#xD;
             ESAs or lenalidomide.&#xD;
&#xD;
          -  Not requiring cytoreductive therapy other than hydroxyurea.&#xD;
&#xD;
          -  BM and peripheral blood myeloblast count &lt; 10%.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of the MDS, CMML and unclassifiable MDS/MPN overlap&#xD;
             syndromes.&#xD;
&#xD;
        For MM participants:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of MM.&#xD;
&#xD;
          -  After failure of available standard treatments such as alkylating agents,&#xD;
             glucocorticoids, immunomodulatory drugs (lenalidomide,pomalidomide, or thalidomide),&#xD;
             proteasome inhibitors (bortezomib or carfilzomib), and daratumumab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior allogeneic stem cell transplantation or a candidate for such&#xD;
             transplantation.&#xD;
&#xD;
          -  Any major surgery within 28 days before the first dose of study drug.&#xD;
&#xD;
          -  Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy,&#xD;
             biological therapy, endocrine therapy, targeted therapy, or antibody or&#xD;
             hypomethylating agent to treat the participant's disease within 5 half-lives or 28&#xD;
             days (whichever is shorter) before the first dose of study drug.&#xD;
&#xD;
          -  Undergoing treatment with another investigational medication or having been treated&#xD;
             with an investigational medication within 28 days before the first dose of study drug.&#xD;
             -Undergoing treatment with ESAs, granulocyte colony-stimulating factor or&#xD;
             granulocyte/macrophage colony-stimulating factor, romiplostin, or eltrombopag at any&#xD;
             time within 28 days before the first dose of study drug.&#xD;
&#xD;
          -  Undergoing treatment with a strong or potent inhibitor or inducer of CYP3A4/5 within&#xD;
             28 days or 5 half-lives (whichever is longer) before the first dose of study drug or&#xD;
             expected to receive such treatment during the study.&#xD;
&#xD;
          -  History of clinically significant or uncontrolled cardiac disease.&#xD;
&#xD;
          -  History or presence of an abnormal ECG that, in the investigator's opinion, is&#xD;
             clinically Meaningful.&#xD;
&#xD;
          -  Presence of chronic or current active infectious disease requiring systemic&#xD;
             antibiotic, antifungal, or antiviral treatment.&#xD;
&#xD;
          -  Diagnosis of chronic liver disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tulane Comprehensive Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi (Aouc)</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irrcs Instituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

